Research suggests that CGAs can efficaciously ameliorate pulmonary arterial hypertension, primarily by directly inhibiting c-Src tyrosine kinase activity and reducing ROS levels, consequently improving pathological proliferation of pulmonary arterial smooth muscle cells (65). This evidence concerns the gene CSK and pulmonary arterial hypertension.